In its latest quarter, Evolus extended its commercial traction with Jeuveau® and Evolysse™ products, delivering revenue that outpaced expectations despite ongoing net losses tied to marketing investment. The company operates under a cash-pay model focused on neurotoxin and dermal fillers sourced internationally, facing stiff competition from entrenched incumbents like AbbVie and Galderma. Regulatory complexities, partner reliance for product approvals, and international supply risks shape its operational landscape. Evolus seeks growth through expanding brand awareness, geographic reach, and product approvals while managing capital structure pressures with $49.8 million cash against $160 million debt as of Q1 2026.